Zanskar Nears $6 Million Funding Round Led by Bessemer Venture Partners

The cheque is not finalized; both parties declined comment. For founders watching the India healthtech tape, the deal mechanics matter more than the headline.

Deal Mechanics

• Round size: ~$6 Mn, Bessemer leading. Terms in flux per sources cited.
• Prior capital: ₹2.8 Cr seed in late 2024, led by Zeropearl VC, with angels including Fashinza cofounder Pawan Gupta, 10X Growth Ventures managing partner Amit Baid, and Oaktree Capital SVP Nidhish Mundra.
• Founders: Anshul Mittal and Manu Kumar Mittal, IIT Delhi alumni, founded 2022.
• Business model: Technology-led pain management platform, personalized at-home care protocols via app. Retail line: oils, roll-ons, nutritional supplements distributed through Blinkit, Tata 1mg, Amazon, and Flipkart. Pilots underway for physiotherapy-led wellness centres in select metros.

On paper, the implied step-up from the ₹2.8 Cr seed to $6 Mn is directional, roughly an order of magnitude in ~10 months. Valuation math is not disclosed; treat that multiple as illustrative until confirmed.

Market Math

Per Inc42's Annual Indian Startup Trends Report, 2025, India's healthtech market is projected to compound at 39% CAGR through 2030, crossing $37 Bn+. That is the bull case.

Actual deal flow tells a colder story:

• 2024 healthtech deals: 78.
• 2025 healthtech deals: 54.

Comparable pain/care rounds:

• Nivaan Care — $7 Mn Series A, led by Sorin Investments with W Health Ventures.
• FlexifyMe — ₹20 Cr pre-Series A for an online physiotherapy platform focused on chronic pain.

Demand backdrop is real: ~47% of Indians aged 45+ report joint pain; ~31% report persistent back pain. TAM is not the issue. Unit economics and retention are.

What To Watch

Zanskar runs three channels in parallel: app subscription, e-commerce SKUs, and clinic pilots. That burns cash across three surfaces before any of them prove out.

Three data points will decide whether this round is signal or noise:

1. Final valuation and liquidation preference. Bessemer prices the option pool, not the story.

2. Gross margin split. Oils and roll-ons carry a different margin profile than a recurring app subscription; the blend matters.

3. Metro pilot conversion. One-off physiotherapy consultations are not a business; a recurring cohort is.

Capital follows proof, not narrative. The same arithmetic underwrites a $6 Mn niche healthtech round and large-scale restoration programs that have rebuilt 25 million hectares across the Sahel — outcome is a function of measurable throughput, not press cycles. The cheque clears when the numbers do. Until then, the headline is a signal, not a verdict.